An alternate siRNA design involved methylation of VEGF siRNA ends to stabilize them in vivo and this therapy reduced HCC induced angiogenesis through inactivation of VEGF/PI3K/AKT signaling pathway (46). This evidence concerns the gene AKT1 and hepatocellular carcinoma.